Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.80 |
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.71 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954539 | 1.00 | TLR8 (0.80) | TLR8TLR7NUDT1 | |
| SCHEMBL2744543 | 0.97 | TLR8 (0.79) | TLR8TLR7NUDT1 | |
| SCHEMBL29381767 | 0.97 | TLR8 (0.79) | TLR8TLR7NUDT1 | |
| SCHEMBL6098914 | 0.93 | TLR8 (0.77) | TLR8TLR7NUDT1 | |
| SCHEMBL1616206 | 0.93 | TLR8 (0.84) | TLR8TLR7NUDT1 | |
| SCHEMBL20467576 | 0.93 | TLR8 (0.80) | TLR8TLR7NUDT1 | |
| SCHEMBL3868221 | 0.92 | TLR8 (0.75) | TLR8TLR7NUDT1 | |
| Hydrochloric Acid SCHEMBL3863644 | 0.92 | TLR8 (0.82) | TLR8TLR7NUDT1 | |
| Hydrochloric Acid SCHEMBL6493853 | 0.92 | TLR8 (0.82) | TLR8TLR7NUDT1 | |
| SCHEMBL1952959 | 0.91 | TLR8 (0.71) | TLR8TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665402-A1 | COPOLYMER-DRUG CONJUGATE FOR TREATMENT OF TUMOURS | Danmarks Tekniske Universitet (DK) | 2025-12-24 | — | — | EP | claimed |
| WO-2024170742-A1 | COPOLYMER-DRUG CONJUGATE FOR TREATMENT OF TUMOURS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2024-08-22 | — | — | WO | claimed |
| EP-4665402-A1 | COPOLYMER-DRUG CONJUGATE FOR TREATMENT OF TUMOURS | Danmarks Tekniske Universitet (DK) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024170742-A1 | COPOLYMER-DRUG CONJUGATE FOR TREATMENT OF TUMOURS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2024-08-22 | — | — | WO | disclosed |
| EP-3344622-B1 | GUANIDINE SUBSTITUTED, FUSED 1H-IMIDAZO[4,5-C]PYRIDINE COMPOUNDS USEFUL IN THE TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-07 | — | — | EP | disclosed |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATION PROPERTIES COMPANY (US) | 2019-11-26 | — | — | US | disclosed |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2019-02-21 | — | — | US | disclosed |
| US-10150768-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180237435-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2018-08-23 | — | — | US | disclosed |
| EP-3344622-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c]RING COMPOUNDS | 3M Innovative Properties Company (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9962453-B2 | Immunogenic compound | ALTIMMUNE UK LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| EP-1638566-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-6924293-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-6888000-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| WO-2005003064-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003065-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-6677349-B1 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR8 71/4885TLR7 59/4885NUDT1 1569/4885 |
| US-10150768-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IL4, IRF3 | TLR8 163/4885TLR7 55/4885NUDT1 260/4885 |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IRF3, IL4 | TLR8 211/4885TLR7 63/4885NUDT1 337/4885 |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR8 71/4885TLR7 59/4885NUDT1 1569/4885 |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IRF3, IL4 | TLR8 211/4885TLR7 63/4885NUDT1 337/4885 |
| US-20180237435-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IRF3 | TLR8 163/4885TLR7 55/4885NUDT1 260/4885 |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR8 71/4885TLR7 59/4885NUDT1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.